Cerevance today announced plans to present an oral presentation at the upcomingAmerican Society of Clinical Psychopharmacology (ASCP) conference, taking place in Miami, Florida, May 30 – June 2, 2023.
Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the NextGeneration of Therapeutic Development conference, taking place in British Columbia,Canada, May 15 – 19, 2023.
Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 2023 RBC Capital Markets Global Healthcare Conference being held May 16-17, 2023. Company management will also be available for virtual one-on-one meetings.
Cerevance today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023
Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming 22nd Annual Needham Healthcare Conference.
Cerevance announced that Ottavio V. Vitolo, M.D., chief medical officer of Cerevance, will participate in a roundtable discussion at the upcoming Chief Medical Officer Summit 360˚ (CMO Summit 360˚).
Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.
Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.
Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.
Cerevance, today announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.
